(Q42608396)

English

Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease

scientific article published on August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 November 2017

Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease (English)

1 reference

Europe PubMed Central

3 November 2017

multicenter clinical trial

0 references

Jaroslaw Kierkus

4

object named as

Jaroslaw Kierkus

1 reference

Europe PubMed Central

3 November 2017

author name string

Brinda K Tammara

1

1 reference

Europe PubMed Central

3 November 2017

Janice E Sullivan

2

1 reference

Europe PubMed Central

3 November 2017

Kim G Adcock

3

1 reference

Europe PubMed Central

3 November 2017

John Giblin

5

1 reference

Europe PubMed Central

3 November 2017

Natalie Rath

6

1 reference

Europe PubMed Central

3 November 2017

Xu Meng

7

1 reference

Europe PubMed Central

3 November 2017

Mary K Maguire

8

1 reference

Europe PubMed Central

3 November 2017

Gail M Comer

9

1 reference

Europe PubMed Central

3 November 2017

Robert M Ward

10

1 reference

Europe PubMed Central

3 November 2017

publication date

1 August 2011

1 reference

Europe PubMed Central

3 November 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

3 November 2017

50

1 reference

Europe PubMed Central

3 November 2017

541-550

1 reference

Europe PubMed Central

3 November 2017

8

1 reference

Europe PubMed Central

3 November 2017

https://scigraph.springernature.com/pub.10.2165/11591900-000000000-00000

0 references

A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

A biodegradable esophageal stent in the treatment of a corrosive esophageal stenosis in a child.

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Gastroesophageal reflux: a critical review of its role in preterm infants

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Are proton pump inhibitors indicated for the treatment of gastroesophageal reflux in infants and children?

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Managing gastro-oesophageal reflux disease in children

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD.

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD).

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Prevention of erosive oesophagitis relapse with pantoprazole

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Bioequivalence among three methods of administering pantoprazole granules in healthy subjects

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Pharmacogenomics of proton pump inhibitors

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Pharmacogenetics and pharmacogenomics.

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Mechanism-based concepts of size and maturity in pharmacokinetics

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Dosing in children

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Review article: similarities and differences among delayed-release proton-pump inhibitor formulations

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Developmental expression of human hepatic CYP2C9 and CYP2C19.

1 reference

https://api.crossref.org/works/10.2165%2F11591900-000000000-00000

21 January 2018

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/21740077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatol

1 reference

https://pubmed.ncbi.nlm.nih.gov/21740077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of pantoprazole in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/21740077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21740077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21740077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21740077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21740077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11591900-000000000-00000

1 reference

Europe PubMed Central

3 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

3 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42608396&oldid=1962778472"